Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Inventory of $571.0 million for Q2 2026, up 32.48% sequentially from $431.0 million in Q1 2026, and up 11.96% YoY from $510.0 million in Q2 2025.
Johnson & Johnson (JNJ) Change in Inventory (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Change in Inventory for 18 years, with the latest figure at $571.0 million in Q2 2026.
- Quarterly Change in Inventory rose 11.96% year-over-year to $571.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 71.87% YoY) and the FY2025 annual result came in at $1.5 billion, up 28.55% from the prior year.
- Change in Inventory climbed to $571.0 million in Q2 2026 per JNJ's latest filing, from $431.0 million in the prior quarter.
- Over five years, Change in Inventory peaked at $1.3 billion in Q1 2023 and troughed at -$124.0 million in Q4 2023.
- A 5-year average of $428.2 million and a median of $411.0 million in 2024 frame the typical range for Change in Inventory.
- The sharpest annual moves came in 2023 and 2026: Change in Inventory tumbled 109.19% in 2023, then jumped 195.21% in 2026.
- Over 5 years, Change in Inventory stood at $600.0 million in 2022, then plunged by 120.67% to -$124.0 million in 2023, then soared by 172.58% to $90.0 million in 2024, then plunged by 48.89% to $46.0 million in 2025, then soared by 1141.3% to $571.0 million in 2026.
- According to Business Quant data, Change in Inventory over the past three periods registered $571.0 million, $431.0 million, and $46.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 571.00 Mn |
| Jun 28, 2026 | 571.00 Mn |
| Mar 29, 2026 | 431.00 Mn |
| Mar 29, 2026 | 431.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Dec 28, 2025 | 46.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Sep 28, 2025 | 748.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Jun 29, 2025 | 510.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Mar 30, 2025 | 146.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Dec 29, 2024 | 90.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Sep 29, 2024 | 299.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Jun 30, 2024 | 391.00 Mn |
| Mar 31, 2024 | 348.00 Mn |
| Mar 31, 2024 | 348.00 Mn |